PuraPharm Corporation Limited (PuraPharm) has reported a stable capital structure for the month ended 30 September 2026, according to its monthly return submitted to the Hong Kong Stock Exchange on 7 October 2026.

Authorised Capital • Authorised share count remained at 5.00 trillion ordinary shares with a par value of USD 0.001, equivalent to authorised share capital of USD 5.00 billion. No changes were recorded during the month.

Issued and Treasury Shares • Issued shares (excluding treasury shares) stood unchanged at 535.90 million. • The company held no treasury shares, and there were no repurchases, cancellations, or transfers during the period. • Consequently, total issued shares also remained at 535.90 million.

Public Float Compliance • PuraPharm confirmed compliance with the Main Board’s minimum public-float requirement of 25% of issued shares as at 30 September 2026.

Equity Incentive Plans • Under the 12 June 2015 Share Option Scheme, 23.96 million share options were outstanding at month-end—unchanged from August. • No options were exercised; therefore, no new shares were issued and no funds were raised in September.

Other Instruments • The company reported no outstanding warrants, convertible securities, or other agreements that could result in share issuance.

Overall, PuraPharm’s September disclosure indicates a steady equity profile with no alterations to its authorised or issued share capital and ongoing adherence to Hong Kong listing requirements.